LLY - ELI LILLY & Co

934.6
83.390   8.923%

Share volume: 8,191,385
Last Updated: 04-30-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$851.21
83.39
0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
59%
Profitability 75%
Dept financing 22%
Liquidity 37%
Performance 57%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.64%
1 Month
-2.09%
3 Months
-10.49%
6 Months
4.25%
1 Year
17.69%
2 Year
20.32%
Key data
Stock price
$934.60
P/E Ratio 
46.82
DAY RANGE
$896.80 - $945.50
EPS 
$23.00
52 WEEK RANGE
$623.78 - $1,133.95
52 WEEK CHANGE
$13.47
MARKET CAP 
966.460 B
YIELD 
0.56%
SHARES OUTSTANDING 
943.357 M
DIVIDEND
$1.73
EX-DIVIDEND DATE
02-13-2026
NEXT EARNINGS DATE
08-07-2025
BETA 
0.81
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,832,126
AVERAGE 30 VOLUME 
$3,195,790
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

Recent news